3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma
68
Lymphoma, Non-Hodgkin
53
Lymphoma, Large B-Cell, Diffuse
47
Hodgkin Disease
42
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Leukemia, Myeloid, Acute
41
Small Cell Lung Carcinoma
37
Leukemia
37
Burkitt Lymphoma
32
Lymphoma, Mantle-Cell
29
Lymphoma, Follicular
28
Lung Neoplasms
20
Carcinoma, Non-Small-Cell Lung
20
Multiple Myeloma
19
Congenital Abnormalities
18
Lymphoma, Large-Cell, Immunoblastic
17
Lymphoma, Large-Cell, Anaplastic
17
Recurrence
15
Lymphoma, B-Cell, Marginal Zone
15
Lymphoma, B-Cell
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Neuroblastoma
13
Neoplasms
13
Myelodysplastic Syndromes
11
Waldenstrom Macroglobulinemia
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma, T-Cell
10
Immunoblastic Lymphadenopathy
10
Sarcoma
9
Myeloproliferative Disorders
9
Interventions
Magnetic Resonance Spectroscopy
2
Everolimus
2
Erlotinib Hydrochloride
2
ribociclib
1
palbociclib
1
olaparib
1
etoposide phosphate
1
erdafitinib
1
X-Rays
1
Sunitinib
1
Specimen Handling
1
Radiotherapy
1
Phantoms, Imaging
1
Nuclear Medicine Department, Hospital
1
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
1
Microarray Analysis
1
Lapatinib
1
Irinotecan
1
Immunologic Techniques
1
Immunohistochemistry
1
Immunoglobulin G
1
Ifosfamide
1
Fluorodeoxyglucose F18
1
Etoposide
1
Donepezil
1
Disulfides
1
Dasatinib
1
Cyproheptadine
1
Carboplatin
1
Blotting, Western
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Familial ependymoma
×
Etoposide
×
Clear all
NCT01032070
2024-12-12
PETEY
Astellas Pharma Inc
Phase 2
Terminated
25 enrolled
23 charts